City of Hope to Present New Cancer Treatments at 2024 ASCO Meeting

Renowned oncologists and researchers from City of Hope® will reveal new data and insights on advancing cancer therapies at the 2024 ASCO Annual Meeting in Chicago from May 31 to June 4. Highlights include:

Breakthroughs in Stem Cell Transplantation
A standout presentation in the 2024 Best of ASCO® program will discuss the use of mismatched unrelated donor peripheral blood stem cell transplantation. Historically, stem cell transplants necessitated a donor with a genetic match to the recipient. However, Dr. Monzr M. Al Malki’s phase 2 trial indicates that using HLA-mismatched unrelated donor stem cells can be nearly as effective. This study showed a 79% survival rate one year post-transplant among older adults with advanced blood cancers, with side effects comparable to those receiving genetically matched donor cells. Such findings could democratize access to lifesaving stem cell transplants, especially for older adults and underrepresented groups.

Advanced Cancer Therapies
City of Hope will also present on the phase 3 CodeBreaK 300 trial, highlighting the combination of sotorasib and panitumumab for KRAS G12C-mutated metastatic colorectal cancer. The trial indicates promising overall survival rates, emphasizing the potential of this combination therapy in targeting treatment-resistant tumors.

Glofitamab for Mantle Cell Lymphoma
In another vital study, the bispecific antibody glofitamab demonstrated sustained response rates in patients with advanced mantle cell lymphoma, a type of non-Hodgkin lymphoma. The trial included patients who had failed multiple previous treatments. Dr. Tycel Phillips noted that many patients achieved complete response with a median duration of 12.6 months, improving their progression-free survival significantly.

DFF332 for Advanced Kidney Cancer
Preliminary data from an ongoing trial on DFF332, an oral hypoxia-inducible factor (HIF)-2α inhibitor, shows considerable potential in treating advanced kidney cancer, particularly clear cell renal cell carcinoma (ccRCC). Dr. Sumanta “Monty” Pal revealed that patients tolerated the treatment well with manageable side effects, with some achieving stable disease or even partial response.

Telehealth and Supportive Care
City of Hope has also explored the role of telehealth in extending supportive care to older adults with cancer in underserved communities. A study led by Dr. Tanyanika Phillips demonstrated that telehealth-based geriatric assessments can effectively identify and address vulnerabilities, leading to improved quality of life and better care outcomes. This approach has shown a high rate of patient satisfaction and successful implementation of recommended interventions.

International Impact of Telehealth
A randomized trial conducted in Brazil under Dr. William Dale’s guidance corroborated the benefits of telehealth-based geriatric assessments. Older adults with metastatic cancer reported better daily functioning and well-being after receiving supportive care through telehealth, emphasizing that this model can be effective even in resource-limited settings.

Additional Highlights
City of Hope will also feature several other significant presentations, including discussions on integrative oncology, advanced diagnostics, and innovative therapies for various cancer types. For instance, Dr. Alexis LeVee will present on the effects of combining palbociclib, pembrolizumab, and endocrine therapy in treating advanced breast cancer, supported by a Merit Award from ASCO.

Conclusion
The array of studies and presentations by City of Hope at the 2024 ASCO Annual Meeting underscores their commitment to pioneering cancer treatment and expanding access to innovative therapies. These efforts aim to improve survival rates and quality of life for cancer patients worldwide, demonstrating the profound impact of their research and clinical advancements.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!